BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verger E, Drion P, Meffre G, Bernard C, Duwez L, Lepareur N, Couturier O, Hindré F, Hustinx R, Lacoeuille F. 68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies. PLoS One 2016;11:e0164626. [PMID: 27741267 DOI: 10.1371/journal.pone.0164626] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lacoeuille F, Arlicot N, Faivre-chauvet A. Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects. Médecine Nucléaire 2018;42:32-44. [DOI: 10.1016/j.mednuc.2017.12.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr. Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne) 2019;6:132. [PMID: 31259173 DOI: 10.3389/fmed.2019.00132] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 11.7] [Reference Citation Analysis]
3 Jaymand M. Chemically Modified Natural Polymer-Based Theranostic Nanomedicines: Are They the Golden Gate toward a de Novo Clinical Approach against Cancer? ACS Biomater Sci Eng 2020;6:134-66. [DOI: 10.1021/acsbiomaterials.9b00802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Lepareur N. Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals? Front Med 2022;9:812050. [DOI: 10.3389/fmed.2022.812050] [Reference Citation Analysis]
5 Labelle M, Ispas‐szabo P, Mateescu MA. Structure‐Functions Relationship of Modified Starches for Pharmaceutical and Biomedical Applications. Starch ‐ Stärke 2020;72:2000002. [DOI: 10.1002/star.202000002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lin M, Ta RT, Kairemo K, Le DB, Ravizzini GC. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives. Cancer Biother Radiopharm 2021;36:237-51. [PMID: 32589458 DOI: 10.1089/cbr.2020.3603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres. Biomed Res Int 2018;2018:1435302. [PMID: 30687734 DOI: 10.1155/2018/1435302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
8 Hum NR, Martin KA, Malfatti MA, Haack K, Buchholz BA, Loots GG. Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry. Sci Rep 2018;8:15013. [PMID: 30302019 DOI: 10.1038/s41598-018-33368-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Esquinas PL, Shinto A, Kamaleshwaran KK, Joseph J, Celler A. Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans. EJNMMI Phys 2018;5:30. [PMID: 30523435 DOI: 10.1186/s40658-018-0227-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Degrauwe N, Hocquelet A, Digklia A, Schaefer N, Denys A, Duran R. Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. Front Pharmacol 2019;10:450. [PMID: 31143114 DOI: 10.3389/fphar.2019.00450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]